tiprankstipranks
Myriad Genetics (CH:MYD)
NASDAQ:MYD
Switzerland Market
MYD
Myriad Genetics
RESEARCH TOOLSreports

Myriad Genetics (MYD) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

MYD Analyst Ratings

Hold
6Ratings
Hold
2 Buy
3 Hold
1 Sell
Based on 6 analysts giving stock ratings to
Myriad
Genetics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MYD Stock 12 Month Forecast

Average Price Target

$6.02
Based on 6 Wall Street analysts offering 12 month price targets for Myriad Genetics in the last 3 months. The average price target is $6.02 with a high forecast of $8.03 and a low forecast of $4.42. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$8.03Average Price Target$6.02Lowest Price Target$4.42
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on CH:MYD
David Westenberg
Piper Sandler
Piper Sandler
CHF6.83
Buy
―
Reiterated
05/12/26
Piper Sandler Sticks to Its Buy Rating for Myriad Genetics (MYGN)
Bank of America Securities Analyst forecast on CH:MYD
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Sell
―
Reiterated
05/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (NASDAQ: COLL), Myriad Genetics (NASDAQ: MYGN) and Mineralys Therapeutics, Inc. (NASDAQ: MLYS)
Guggenheim Analyst forecast on CH:MYD
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
05/06/26
Guggenheim Sticks to Their Hold Rating for Myriad Genetics (MYGN)
Craig-Hallum Analyst forecast on CH:MYD
William Bonello
Craig-Hallum
Craig-Hallum
CHF8.03
Buy
―
Assigned
05/06/26
Analysts Offer Insights on Healthcare Companies: Myriad Genetics (NASDAQ: MYGN) and Dianthus Therapeutics (NASDAQ: DNTH)
Wells Fargo Analyst forecast on CH:MYD
Brandon Couillard
Wells Fargo
Wells Fargo
CHF4.82→CHF4.42
Hold
―
Reiterated
05/06/26
Wells Fargo Reaffirms Their Hold Rating on Myriad Genetics (MYGN)
TD Cowen Analyst forecast on CH:MYD
Kyle Boucher
TD Cowen
TD Cowen
CHF5.62→CHF4.82
Hold
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Myriad Genetics (NASDAQ: MYGN) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
UBS Analyst forecast on CH:MYD
Lu Li
UBS
UBS
CHF6.42→CHF4.82
Hold
―
Reiterated
02/25/26
Myriad Genetics price target lowered to $6 from $8 at UBSMyriad Genetics price target lowered to $6 from $8 at UBS
Raymond James Analyst forecast on CH:MYD
Andrew Cooper
Raymond James
Raymond James
CHF5.24→CHF6.42
Buy
―
Reiterated
01/13/26
Raymond James Remains a Buy on Myriad Genetics (MYGN)
Leerink Partners Analyst forecast on CH:MYD
Puneet Souda
Leerink Partners
Leerink Partners
CHF5.62→CHF7.23
Hold
―
Reiterated
08/06/25
Leerink Partners Sticks to Its Hold Rating for Myriad Genetics (MYGN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on CH:MYD
David Westenberg
Piper Sandler
Piper Sandler
CHF6.83
Buy
―
Reiterated
05/12/26
Piper Sandler Sticks to Its Buy Rating for Myriad Genetics (MYGN)
Bank of America Securities Analyst forecast on CH:MYD
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Sell
―
Reiterated
05/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (NASDAQ: COLL), Myriad Genetics (NASDAQ: MYGN) and Mineralys Therapeutics, Inc. (NASDAQ: MLYS)
Guggenheim Analyst forecast on CH:MYD
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
05/06/26
Guggenheim Sticks to Their Hold Rating for Myriad Genetics (MYGN)
Craig-Hallum Analyst forecast on CH:MYD
William Bonello
Craig-Hallum
Craig-Hallum
CHF8.03
Buy
―
Assigned
05/06/26
Analysts Offer Insights on Healthcare Companies: Myriad Genetics (NASDAQ: MYGN) and Dianthus Therapeutics (NASDAQ: DNTH)
Wells Fargo Analyst forecast on CH:MYD
Brandon Couillard
Wells Fargo
Wells Fargo
CHF4.82→CHF4.42
Hold
―
Reiterated
05/06/26
Wells Fargo Reaffirms Their Hold Rating on Myriad Genetics (MYGN)
TD Cowen Analyst forecast on CH:MYD
Kyle Boucher
TD Cowen
TD Cowen
CHF5.62→CHF4.82
Hold
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Myriad Genetics (NASDAQ: MYGN) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
UBS Analyst forecast on CH:MYD
Lu Li
UBS
UBS
CHF6.42→CHF4.82
Hold
―
Reiterated
02/25/26
Myriad Genetics price target lowered to $6 from $8 at UBSMyriad Genetics price target lowered to $6 from $8 at UBS
Raymond James Analyst forecast on CH:MYD
Andrew Cooper
Raymond James
Raymond James
CHF5.24→CHF6.42
Buy
―
Reiterated
01/13/26
Raymond James Remains a Buy on Myriad Genetics (MYGN)
Leerink Partners Analyst forecast on CH:MYD
Puneet Souda
Leerink Partners
Leerink Partners
CHF5.62→CHF7.23
Hold
―
Reiterated
08/06/25
Leerink Partners Sticks to Its Hold Rating for Myriad Genetics (MYGN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Myriad Genetics

3 Months
Michael RyskinBank of America Securities
Success Rate
7/9 ratings generated profit
78%
Average Return
+20.17%
Copying Michael Ryskin's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +20.17% per trade.
1 Year
Michael RyskinBank of America Securities
Success Rate
7/9 ratings generated profit
78%
Average Return
+24.79%
Copying Michael Ryskin's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +24.79% per trade.
2 Years
Michael RyskinBank of America Securities
Success Rate
6/9 ratings generated profit
67%
Average Return
+20.87%
Copying Michael Ryskin's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +20.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MYD Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
1
1
3
3
3
Buy
3
1
0
0
0
Hold
6
4
3
3
3
Sell
1
1
1
1
1
Strong Sell
0
0
0
0
0
total
11
7
7
7
7
In the current month, MYD has received 3 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. MYD average Analyst price target in the past 3 months is 6.02.
Each month's total comprises the sum of three months' worth of ratings.

MYD Financial Forecast

MYD Earnings Forecast

Next quarter’s earnings estimate for MYD is -$0.05 with a range of -$0.10 to $0.02. The previous quarter’s EPS was -$0.07. MYD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year MYD has Performed in-line its overall industry.
Next quarter’s earnings estimate for MYD is -$0.05 with a range of -$0.10 to $0.02. The previous quarter’s EPS was -$0.07. MYD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year MYD has Performed in-line its overall industry.

MYD Sales Forecast

Next quarter’s sales forecast for MYD is $166.53M with a range of $165.70M to $168.21M. The previous quarter’s sales results were $161.99M. MYD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year MYD has Performed in-line its overall industry.
Next quarter’s sales forecast for MYD is $166.53M with a range of $165.70M to $168.21M. The previous quarter’s sales results were $161.99M. MYD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year MYD has Performed in-line its overall industry.

MYD Stock Forecast FAQ

What is CH:MYD’s average 12-month price target, according to analysts?
Based on analyst ratings, Myriad Genetics’s 12-month average price target is 6.02.
    What is CH:MYD’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:MYD, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Myriad Genetics a Buy, Sell or Hold?
        Myriad Genetics has a consensus rating of Hold, which is based on 2 buy ratings, 3 hold ratings and 1 sell ratings.
          What is Myriad Genetics’s share price target?
          The average share price target for Myriad Genetics is 6.02. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $8.03 ,and the lowest forecast is $4.42. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Myriad Genetics?
            Myriad Genetics’s analyst rating consensus is a Hold. This is based on the ratings of 6 Wall Streets Analysts.
              How can I buy shares of Myriad Genetics?
              To buy shares of CH:MYD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.